+44 20 8123 2220
info@marketpublishers.com

Ophthalmic Drugs: World Market Prospects 2013-2023

https://marketpublishers.com/r/O13ECFEB8C0EN.html
Date: March 2013
Pages: 222
Price: US$ 2,635.00 (Single User License)
ID: O13ECFEB8C0EN

Abstracts

Report Details

How to find trends and revenue predictions for the ophthalmic drug industry

What are the commercial prospects for treating eye disorders? Visiongain's new report gives you forecasted revenues to 2023. It explains trends, opportunities and prospects for ocular drugs.

Our study lets you assess sales data at overall world market, submarket and national level. There you find that industry's most promising and lucrative segments, helping your research and analyses.

Therapies for treating eye disorders and diseases have rising demand. See the future of ophthalmic medicines and discover how sales of ocular drugs can increase.

Forecasts and other analyses to help you stay ahead in knowledge

In our work you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (inc. SWOT), business outlooks and research and development (R&D). You receive 48 tables, 74 charts and 9 interviews.

Is finding commercial details a challenge? With our report you can get ahead in knowledge, benefiting your research, analyses and decisions. Find trends, innovations and opportunities. You see what's happening.

Discover areas that will prosper, reducing the risk of your being left behind.

The following sections show how you benefit from our new study.

+44 20 8123 2220
info@marketpublishers.com

Discover prospects for the world market and submarkets

Along with revenue prediction for the overall world market, you see forecasts to 2023 for these five submarkets:

- Glaucoma treatments
- Anti-allergy, anti-inflammatory and anti-infective agents
- Retinal disorder treatments
- Dry eye treatments
- Other medicines.

With our investigation you gain business research and analysis with individual sales predictions and discussions. You find analysis of competition, as well as commercial drivers and restraints. See what's likely to achieve the most success.

You can gain competitive advantages by understanding the trends, opportunities and challenges facing the ophthalmic drug market.

See revenue forecasts for products

How will leading ophthalmic drugs perform to 2023 at world level? Our work shows you revenue forecasts for 20 top products, including Lucentis, Eylea, Visudyne, Xalatan/Xalacom, Patanol and Restasis.

Discover how high revenues can go, to 2023, finding areas and years with highest predicted growth. You see what's happening, understanding trends, challenges and opportunities.

Our work also breaks the main world forecast into leading geographical markets.

What prospects for leading countries?

Developments worldwide will influence the market, especially rising demand in

+44 20 8123 2220
info@marketpublishers.com

emerging countries. Our report shows outlooks for the industry.

You see individual forecasts to 2023 for ten national markets, getting overall revenues:

US

Japan

Germany, France, UK, Italy and Spain (EU5)

Brazil, India and China

Discover progress and outlooks. You assess the industry's future - hear about developments and find their significance.

You find potential. Our analyses show growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2013 to 2023 will change medical prescribing and the commercial landscape.

Research and development - assess innovation, trends and possibilities

What about R&D - the pipeline for new drugs? You see trends for these areas:

Glaucoma treatments

Anti-allergy, anti-inflammatory and anti-infective agents

Retinal disorder treatments

Dry eye treatments

Other progress in ophthalmic treatments.

Our study also discusses these candidates and others:

Neuroprotective agents

RNA interference technology

Ocular implants

Gene therapy.

There's strong, promising R&D for treating ocular disorders. Novel compounds and new formulations with high safety, efficacy and affordability are in great demand. See what's happening.

What affects ophthalmic drugs treatments from 2013?

Our report discusses issues and events affecting that industry and market from 2013 onwards:

Increasing prevalence of eye disorders

Reimbursement for ophthalmic pharmaceuticals

Patient compliance

Generic competition.

Also, we discuss these aspects of the field:

Development of new drug delivery methods and formulations

Sustained-release ocular Implants

New ophthalmic therapeutic applications for drugs.

See what the future holds. You investigate technological, economic and political matters, finding emphasis on companies, competition and business outlooks.

Leading companies and 2015 market value

+44 20 8123 2220
info@marketpublishers.com

We predict the overall world market for ophthalmic drugs will reach $21.9bn in 2015, and expand further to 2023.

What are leading companies doing? Our work discusses Allergan, Novartis, Pfizer, Roche and other pharmaceutical companies, evaluating prospects of the industry and market.

Prospects for R&D are strong, and from 2013 onwards there will arise many opportunities. Our work shows you the technological and commercial possibilities, helping you stay ahead.

Eight ways Ophthalmic Drugs: World Market Prospects 2013-2023 helps

To sum up, our investigation gives you the following knowledge:

Revenues to 2023 for the overall world market and 5 submarkets - you discover that industry's prospects

Forecasting to 2023 for the US, Japan, Germany, France, UK, Spain, Italy, Brazil, India and China - you see leading national sales potentials

Discover revenue forecasts to 2023 for 20 leading products -- you find sales outlooks for top brands

Review R&D, seeing pipeline trends by therapeutic area - you hear about progress in those research areas, finding technological and medical possibilities

Opinions on the sector - you read our industry interviews

Understanding of competition and opportunities - you see what affects that industry, learning what shapes its future

Analysis of what stimulates and restrains the industry and market - you assess challenges and strengths

Prospects for established firms and those seeking to enter the sector - you explore needs, practices and outlooks for success.

+44 20 8123 2220
info@marketpublishers.com

You gain information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, also saving time and getting you recognition for insight.

You see prospects for ophthalmic drugs by ordering now

Visiongain's new study is for everyone needing analysis of the industry and market for ophthalmic medicines. You find data, trends and predictions. Please order our report now.

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

Market Publishers
+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

12. CONCLUSIONS

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

About

Lucentis Controls the Retinal Disorder Market in 2011

Sales of Lucentis (ranibizumab, Genentech/Roche/Novartis), indicated for the treatment of patients with wet AMD, were $3772m in 2011 and $2935m in 2010 compared to $2338m for the fiscal year 2009 (Table 6.2 and Figure 6.2). In 2007 rapid domination of the wet AMD market occurred, when Lucentis revenues grew to $1208m, and increased further to $1761m in 2008.Lucentis is an antibody fragment (recombinant humanised IgG1 kappa isotype monoclonal antibody fragment), which binds to and inhibits the biologic activity of vascular endothelial growth factor A (VEGF-A), a growth factor essential for the formation of new blood vessels. By binding to VEGF-A, Lucentis reduces abnormal vessel growth and leakage of fluid into the retina. This allows the retinal structure to return to normal. Lucentis is the first such treatment that has been shown to improve vision rather than simply slow vision loss. Lucentis stabilises vision in most wet AMD patients treated, and improves vision and vision-related quality of life in a significant number of patients, reports indicate. Lucentis is recommended to be administered by intravitreous injection once a month.

Genentech/Roche markets Lucentis in the US, where the FDA approved the drug in June 2006. Lucentis was Roche's number ten best selling pharmaceutical product in 2008. It maintained that position in 2009, generating sales revenues of $1121m for the company. Roche reported annual revenues for the drug of 1,523CHF ($1402m) for 2010 and $1722m in 2011. Novartis markets Lucentis outside the US, and achieved $1217m in sales in 2009. Novartis reported sales of $1533m and $2050m for the 12 month period to Q4 in 2010 and 2011 respectively. Lucentis was approved for use in the EU in January 2007 and is now marketed in many markets worldwide, including Japan since April 2009.

Visudyne was the Second Highest Selling Retinal Disorder Drug in 2011

Visudyne (verteporfin, QLT/Novartis) is indicated for the treatment of patients with the predominantly classic variant of AMD (comprising about a quarter of AMD patients). Therapy involves intravenous infusion of Visudyne, followed by exposure of the eye to a non-thermal diode laser. This activates the drug and produces a reaction that destroys abnormal blood vessels. Visudyne therapy is typically given approximately every three months and as many times as needed, to prevent re-growth of abnormal blood vessels (typically six to seven treatments over two to three years). Visudyne does not restore vision, however. The FDA approved Visudyne in 2000, and it is now marketed worldwide. Visudyne was the second-highest selling retinal disorder drug of 2009, with total revenues of $106m. Sales in 2010 declined to $91m, a decline of 14.5% over the previous year. In 2011 sales remained steady to record $90m.

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Ophthalmic Drugs: World Market Prospects 2013-2023

Product link: https://marketpublishers.com/r/O13ECFEB8C0EN.html

Price: US$ 2,635.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/O13ECFEB8C0EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _______________________________________

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970